AP2003002873A0 - Pregabalin lactose conjugates - Google Patents

Pregabalin lactose conjugates

Info

Publication number
AP2003002873A0
AP2003002873A0 APAP/P/2003/002873A AP2003002873A AP2003002873A0 AP 2003002873 A0 AP2003002873 A0 AP 2003002873A0 AP 2003002873 A AP2003002873 A AP 2003002873A AP 2003002873 A0 AP2003002873 A0 AP 2003002873A0
Authority
AP
ARIPO
Prior art keywords
disorders
pregabalin lactose
disease
pregabalin
subject
Prior art date
Application number
APAP/P/2003/002873A
Other languages
English (en)
Inventor
Timothy Robert Hurley
Michael James Lovdahl
Brian TOBIAS
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AP2003002873A0 publication Critical patent/AP2003002873A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/2003/002873A 2001-03-30 2002-02-25 Pregabalin lactose conjugates AP2003002873A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28017601P 2001-03-30 2001-03-30
PCT/IB2002/000647 WO2002078747A2 (en) 2001-03-30 2002-02-25 Pregabalin lactose conjugates

Publications (1)

Publication Number Publication Date
AP2003002873A0 true AP2003002873A0 (en) 2003-09-30

Family

ID=23072002

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2003/002873A AP2003002873A0 (en) 2001-03-30 2002-02-25 Pregabalin lactose conjugates

Country Status (32)

Country Link
US (1) US7022678B2 (OSRAM)
EP (1) EP1377318A2 (OSRAM)
JP (1) JP2004524357A (OSRAM)
KR (1) KR20040008146A (OSRAM)
CN (1) CN1511043A (OSRAM)
AP (1) AP2003002873A0 (OSRAM)
AR (1) AR033024A1 (OSRAM)
BG (1) BG108193A (OSRAM)
BR (1) BR0208439A (OSRAM)
CA (1) CA2440468C (OSRAM)
CZ (1) CZ20032547A3 (OSRAM)
DO (1) DOP2002000356A (OSRAM)
EA (1) EA200300954A1 (OSRAM)
EC (1) ECSP034740A (OSRAM)
EE (1) EE200300480A (OSRAM)
GT (1) GT200200051A (OSRAM)
HU (1) HUP0303956A2 (OSRAM)
IL (1) IL157879A0 (OSRAM)
IS (1) IS6912A (OSRAM)
MA (1) MA27004A1 (OSRAM)
MX (1) MXPA03007437A (OSRAM)
NO (1) NO20034348D0 (OSRAM)
OA (1) OA12456A (OSRAM)
PA (1) PA8542101A1 (OSRAM)
PE (1) PE20021016A1 (OSRAM)
PL (1) PL369179A1 (OSRAM)
SK (1) SK11832003A3 (OSRAM)
SV (1) SV2003000928A (OSRAM)
TN (1) TNSN02038A1 (OSRAM)
UY (1) UY27233A1 (OSRAM)
WO (1) WO2002078747A2 (OSRAM)
ZA (1) ZA200306608B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
WO2007035890A1 (en) 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. An asymmetric synthesis of ( s ) - ( + ) -3- (aminomethyl) -5-methylhexanoic acid
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010115612A2 (en) 2009-04-10 2010-10-14 Synthon B.V. Pregabalin compositions
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104370986B (zh) * 2014-10-28 2017-07-04 河南中烟工业有限责任公司 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用
CN104311608B (zh) * 2014-10-28 2016-10-05 河南中烟工业有限责任公司 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用
CN105520918B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊
CN105434395B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
KR100697734B1 (ko) * 1998-10-16 2007-03-22 워너-램버트 캄파니 엘엘씨 조증 및 양극성 장애 치료용 제약 조성물
IL155704A0 (en) * 2000-11-30 2003-11-23 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
US7022678B2 (en) 2006-04-04
WO2002078747A8 (en) 2003-12-04
IS6912A (is) 2003-08-14
BG108193A (en) 2004-09-30
PA8542101A1 (es) 2002-10-28
KR20040008146A (ko) 2004-01-28
US20020187941A1 (en) 2002-12-12
WO2002078747A2 (en) 2002-10-10
UY27233A1 (es) 2002-10-31
AR033024A1 (es) 2003-12-03
PL369179A1 (en) 2005-04-18
TNSN02038A1 (fr) 2005-12-23
OA12456A (en) 2004-08-24
PE20021016A1 (es) 2002-11-14
CA2440468C (en) 2008-09-02
MXPA03007437A (es) 2003-11-18
EA200300954A1 (ru) 2004-02-26
NO20034348L (no) 2003-09-29
ECSP034740A (es) 2003-12-24
WO2002078747A3 (en) 2003-10-09
EE200300480A (et) 2003-12-15
MA27004A1 (fr) 2004-12-20
EP1377318A2 (en) 2004-01-07
SK11832003A3 (sk) 2004-04-06
CN1511043A (zh) 2004-07-07
ZA200306608B (en) 2004-11-25
SV2003000928A (es) 2003-07-29
CA2440468A1 (en) 2002-10-10
BR0208439A (pt) 2004-03-23
JP2004524357A (ja) 2004-08-12
DOP2002000356A (es) 2002-12-15
CZ20032547A3 (en) 2004-04-14
NO20034348D0 (no) 2003-09-29
HUP0303956A2 (hu) 2004-04-28
GT200200051A (es) 2002-11-15
WO2002078747A9 (en) 2003-12-31
IL157879A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
BG108193A (en) Pregabalin lactose conjugates
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR0114316A (pt) Processo para a preparação de formulações em pó
PL357389A1 (en) Bupropion metabolites and methods of their synthesis and use
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
SG157231A1 (en) Substituted p-diaminobenzene derivatives
MX348062B (es) Mutantes que degradan proteoglicanos para tratamiento del snc.
MY135838A (en) Methods for the treatment of mental disorders
EA200301063A1 (ru) Фармацевтические агенты для лечения ганв и микроаденом
AU2003277280A1 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
PL321956A1 (en) Derivative compounds of 4-aminotetrahydrobenzoxazole or -isothiazole
ES2144698T3 (es) Procedimiento para preparar un derivado de biciclohexano.
JO2260B1 (en) Piperidine ethanesulfonyl derivatives
CR7060A (es) Conjugados de pregabalina-lactosa
BR0308753A (pt) Método para produzir pseudo-ilhotas
UA30659A (uk) Спосіб купіровання опіатної залежності
UA4433U (uk) Спосіб корекції прихованих порушень вуглеводного обміну у експериментальних тварин
WO2005053697A3 (en) Treatment of sexual disorders